News from 2010

Vascular Pathways Completes Series B Financing

Vascular Pathways Inc., a privately held medical device company with a breakthrough product for peripheral intravenous access, has announced the closing of a $14 million Series B financing round

Aegerion Pharmaceuticals Announces Pricing of Initial Public Offering

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announces the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share

Gedeon Richter Announces Acquisition of PregLem

Richter announces the Acquisition of PregLem for an initial cash consideration of CHF150 million and further milestone payments of up to CHF295 million

PregLem Announces Additional Positive Phase III Results for Esmya

PregLem, a biopharmaceutical company focused on women’s reproductive medicine, announces positive Phase III data from its second pivotal study for Esmya (TM)

PregLem Announces Positive Phase III Results for Esmya as an Effective Treatment for Uterine Fibroids

PregLem, a biopharmaceutical company focused on women’s reproductive medicine, announces positive Phase III results of Esmya(TM)

Cheetah Medical Closes $20 million Series B Financing

Cheetah Medical, Inc., a worldwide leader in noninvasive haemodynamic and cardiac output monitoring technology, announces the closing of a $20 million financing round

Galapagos acquires Argenta Discovery’s service operations

Galapagos NV announces the acquisition of Argenta Discovery 2009 Ltd. The combination with Galapagos’ service division BioFocus creates one of the world’s largest drug discovery service organisations

Vantia Therapeutics' Lead Candidate VA106483 enters Phase IIb Trial for Nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia